These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33618649)

  • 21. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
    Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
    Azad NA; Shah ZA; Pandith AA; Rasool R; Jeelani S
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
    Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
    Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
    Ma W; Tseng R; Gorre M; Jilani I; Keating M; Kantarjian H; Cortes J; O'Brien S; Giles F; Albitar M
    Haematologica; 2007 Feb; 92(2):170-5. PubMed ID: 17296565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
    Moumen A; Dehbi H; Kottwitz D; El Amrani M; Bouchoutrouch N; El Hadi H; Quessar A; Benchekroun S; Nadifi S; Sefrioui H
    Genet Mol Res; 2015 Feb; 14(1):1044-55. PubMed ID: 25730044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
    Ashariati A; Ugroseno S
    Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
    Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
    Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
    Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
    Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
    Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
    Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
    Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
    Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
    Ann Hematol; 2000 Aug; 79(8):424-31. PubMed ID: 10985361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.